What Is Peptide Therapy? Definition and What Research Reports

Plain-language definition

"Peptide therapy" is an umbrella phrase for using a peptide — a short chain of amino acids — as a therapeutic agent. Amino acids are the building blocks of proteins; when only a handful to a few dozen are linked together, the molecule is called a peptide rather than a protein. Because the body already uses peptides as hormones and signalling molecules, researchers have long asked whether synthetic or modified peptides can be given as drugs to interact with the same receptors and pathways. The phrase covers everything from decades-old hospital medicines to molecules that have never left a laboratory bench, which is why it means very little on its own.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or symptom. Nothing here describes how any substance should be used.

The biochemical definition

In biochemistry, a peptide is a polymer of amino acids joined by peptide bonds. The boundary with "protein" is conventional rather than absolute, and is usually drawn somewhere around 40–50 residues. Peptides sit between small-molecule drugs and large biologics: they are big enough to bind receptor surfaces with high specificity, but small enough to be made by chemical synthesis. Their weaknesses are equally characteristic — most are digested in the gut and cleared quickly from blood, which is why so much peptide research concerns delivery, stabilisation and formulation. A 2024 nanomedicine study, for example, combined a peptide agonist with a reactive-oxygen-species-sensitive PEG-PPS-PEG carrier and evaluated targeted delivery in a mouse model, an approach the researchers framed as a way to address peptide instability rather than a claim about any human outcome (PMID 39253061).

The regulatory definition, and why it differs

Regulators do not approve "peptide therapy." They approve specific products for specific indications. Insulin, and later a range of peptide hormones and analogues, have been approved medicines for decades, and peptide radiopharmaceuticals are used in nuclear medicine departments. Everything outside that approval framework falls into other categories: compounded preparations, which are prepared for an individual patient under pharmacy rules rather than approved as products; investigational agents studied under research authorisation; and materials labelled "research use only" (RUO), which are sold for laboratory work and are not evaluated as medicines for people. A 2026 primer written for orthopaedic and sports medicine physicians discussed injectable peptides as a category clinicians are increasingly asked about, and framed the regulatory and evidence status of these agents as a core part of the conversation (PMID 41476424). The same label — "peptide therapy" — can therefore describe an approved hospital medicine or an unapproved laboratory chemical.

How the term is used in the research literature

Published papers rarely use "peptide therapy" as a standalone concept. Instead they name a molecule, a target and a model system. The table below shows how the phrase maps onto distinct research areas.

Where the term is misused

• Treating it as one treatment. "Peptide therapy" is a chemical class, not a therapy with a single evidence base. Grouping an approved radiopharmaceutical with a preclinical laboratory peptide under one heading obscures the difference in evidence.
• Conflating "anti-peptide" with "peptide." In headache medicine, anti-CGRP therapy targets an endogenous peptide; a retrospective US chart review examined effectiveness and tolerability of anti-CGRP therapy for migraine and other chronic headaches in adolescents and young adults (PMID 39335375). That is the opposite direction from administering a peptide as a drug, yet both are labelled "peptide therapy."
• Reading animal or cell findings as human evidence. Much of the literature searched by newcomers is preclinical. A 2019 study reported that the M10 peptide attenuated silica-induced pulmonary fibrosis in an experimental model and linked the effect to inhibition of Smad2 phosphorylation (PMID 31125577). Such mechanistic results describe biology in a model system, not outcomes in people.
• Assuming a mechanism transfers. A review of anticancer peptides described mechanisms ranging from simple membrane disruption to complex intracellular signalling effects, and noted that mechanism diversity complicates translation (PMID 36195187).
• Using "therapy" to imply approval. The word signals intent, not regulatory standing.

Related terms

• Peptide drug — a specific approved or investigational product, rather than a category.
• Peptide receptor radionuclide therapy (PRRT) — a receptor-targeting peptide carrying a therapeutic radioisotope, described in a 2022 review of [¹⁷⁷Lu]Lu-DOTA-TATE (PMID 34920969).
• Peptide immunotherapy — use of short antigen-derived sequences to modify immune responses, reviewed in 2006 (PMID 16701147).
• Antimicrobial and antiviral peptides — sequences that interfere with pathogens; one study reported that a tegument protein pp150 sequence-specific peptide blocked cytomegalovirus infection in laboratory experiments (PMID 34835083).
• Peptide mimetic — a modified structure designed to reproduce peptide binding with greater stability.
• Research use only (RUO) — a label indicating material intended for laboratory research, not human treatment.

What the published literature reports about the category

The evidence behind the phrase is uneven, and reading it by tier is the clearest way to make sense of it.

Clinical literature

Peptide receptor radionuclide therapy is the most established example of a peptide-based treatment used in hospital practice; a 2022 review in a nuclear medicine journal summarised the use of [¹⁷⁷Lu]Lu-DOTA-TATE, in which a somatostatin-receptor-binding peptide delivers a radioisotope to receptor-expressing tumours (PMID 34920969). In headache care, researchers conducted a retrospective study in the USA of anti-CGRP therapy in adolescents and young adults and reported on both effectiveness and tolerability in that population (PMID 39335375). A 2026 primer summarised the injectable peptide landscape for orthopaedic and sports medicine physicians, emphasising what is and is not supported (PMID 41476424).

Preclinical literature

Most peptides discussed online sit here. Studies of the stable gastric pentadecapeptide BPC 157 have examined striated, smooth and heart muscle in a body of animal and laboratory work reviewed in 2022 (PMID 36551977), and a 2025 rat study investigated it after surgical detachment of the quadriceps muscle from its attachments, with muscle-to-bone reattachment as the outcome of interest (PMID 39861766). Separately, researchers examined C-peptide replacement and reported on bone microarchitecture parameters in streptozotocin-diabetic rats (PMID 32607636). Design-stage work includes the PD-1/PD-L1 peptide inhibitor developed through rational design (PMID 29920293).

Tolerability and Adverse Events: What Studies Report

Because "peptide therapy" spans many molecules, safety information cannot be generalised across the category. Published safety data attach to specific agents in specific settings: the retrospective anti-CGRP study assessed tolerability alongside effectiveness in adolescents and young adults (PMID 39335375), and the PRRT review addressed a radiopharmaceutical administered under nuclear medicine supervision, where dosimetry and monitoring are part of the procedure (PMID 34920969). For unapproved injectable peptides, the 2026 primer discussed the absence of comparable safety datasets as a central limitation clinicians should weigh (PMID 41476424). Preclinical papers such as the BPC 157 muscle literature and the C-peptide bone study describe animal models and do not establish human safety profiles (PMID 36551977, PMID 32607636).

Reading the term critically

1. Identify the specific molecule, not the category.
2. Check the model: cells, animals or people.
3. Check the direction: is a peptide the drug, the target, or the delivery vehicle?
4. Check regulatory standing separately from published findings.
5. Treat mechanism papers as hypotheses about biology, not statements about outcomes.

References

• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE (Revista Espanola de Medicina Nuclear e Imagen Molecular, 2022)
• Effects of C-Peptide Replacement Therapy on Bone Microarchitecture Parameters in Streptozotocin-Diabetic Rats (Calcified Tissue International, 2020)
• M10 peptide attenuates silica-induced pulmonary fibrosis by inhibiting Smad2 phosphorylation (Toxicology and Applied Pharmacology, 2019)
• Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA (Brain Sciences, 2024)
• Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction (Cancer Letters, 2018)
• Combined ROS Sensitive PEG-PPS-PEG with Peptide Agonist for Effective Target Therapy in Mouse Model (International Journal of Nanomedicine, 2024)
• Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle (Biomedicines, 2022)
• Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats (Pharmaceutics, 2025)
• Anticancer peptides mechanisms, simple and complex (Chemico-Biological Interactions, 2022)
• Peptide immunotherapy (Immunology and Allergy Clinics of North America, 2006)
• Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection (Viruses, 2021)